Company intelligence / Profile preview
Kimia Therapeutics
Berkeley, California, United Stateskimiatx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Kimia Therapeutics has not yet reported clinical results. The company focuses on preclinical drug discovery using its proprietary ATLAS platform to generate and screen novel small molecule compounds targeting a broad range of diseases including cancer, immunological, and inflammatory disorders. No clinical candidates or trial outcomes have been announced as of May 2025. [4][5][8]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesNovel chemical libraries
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Carmot Therapeutics (collaboration on metabolic programs)
Beyond the preview
Go deeper on Kimia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kimia Therapeutics.